Edoxaban Versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism  

作　　者：史振宇 

机构地区：[1]复旦大学附属中山医院血管外科研究所

出　　处：《临床误诊误治》2014年第3期102-102,共1页Clinical Misdiagnosis & Mistherapy

摘　　要：By the end of last year,a group of investigators led by Professor Büller HR accomplished the global HOKUSAI-VTE trial which was funded by Daiichi-Sankyo.They conducted this trial to investigate whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism.Edoxaban is a newly developed oral factor Xa direct inhibitor withBy the end of last year, a group of investigators led by Professor Btiller HR accomplished the global HOKUSAI-VTE trial which was funded by Daiichi-Sankyo. They conducted this trial to investigate whether the oral factor Xa inhibitor edoxaban can be an alterna- tive to warfarin in patients with venous thromboembolism. Edoxaban is a newly developed oral factor Xa direct inhibitor with stable pharmacodynamics and pharmacoefficacy in spite of race, age, gender, body weight and very few interaction with food and drug. The study was designed as a randomized, double-blind, noniuferiority one which randomly assigned patients with acute venous thromboem- bolism including DVT and/or PE, who had initially received heparin （mostly enoxaparin） , to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily （ e. g. , in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg） or to receive standard warfarin therapy. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was re- current symptomatic venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding.

关 键 词：新陈代谢 血栓 疾病 临床分析 

分 类 号：R543.6[医药卫生—心血管疾病]